San Diego-based Cadence Pharmaceuticals Inc. (Nasdaq: CADX) has announced a preliminary estimate of net product revenue from sales of its Ofirmev acetaminophen injection for the three months ended Dec. 31, 2012.
12481 High Bluff Dr. Ste., 200
San Diego, CA 92130
All contents herein copyright San Diego Source | The Daily Transcript ® 1994-2013